Spectrum Pharma (SPPI) Shares Falling Amid FDA Notice of Unidentified Generic Co. Selling Copies of Fusilev Injections
Tweet
Share
E-mailGet Alerts SPPI Hot Sheet
Price: $1.03 --0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 14.6%
EPS Growth %: +100.0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 14.6%
EPS Growth %: +100.0%
Join SI Premium – FREE
Shares of Spectrum Pharma (Nasdaq: SPPI) are tumbling in early-morning trade following an FDA notice which discloses an unidentified generic company has applied to sell copies of Suilev injections.
The stock is now down more than 7 percent.
The stock is now down more than 7 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- B. Riley Financial (RILY) touching day low of $27, giving back half the day's gains
- Analysts favorite fintech stock Adyen tumbles after revenue miss
Create E-mail Alert Related Categories
FDA, Hot FDA News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
